Major
Established
説明
Carbamazepine dramatically reduces aripiprazole plasma levels through potent CYP3A4 induction, potentially rendering antipsychotic treatment ineffective.
機序
Carbamazepine induces CYP3A4, the primary enzyme metabolizing aripiprazole, reducing aripiprazole AUC by approximately 70%.
臨床的意義
Psychiatric relapse due to sub-therapeutic aripiprazole levels is a major risk; FDA labeling explicitly requires a dose doubling.
対処法
Double aripiprazole dose when co-prescribed with carbamazepine per FDA label; monitor clinical response and reduce dose if carbamazepine is discontinued.